Oncology Institute Net Income Over Time
| TOIIW Stock | USD 0.10 0.02 16.67% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Oncology Institute Performance and Oncology Institute Correlation. What growth prospects exist in Health Care Equipment & Supplies sector? Can Oncology capture new markets? Factors like these will boost the valuation of Oncology Institute. If investors know Oncology will grow in the future, the company's valuation will be higher. Valuation analysis balances hard financial data with qualitative growth assessments. While each Oncology Institute valuation metric matters, prioritizing which indicators carry greater predictive weight remains essential.
Earnings Share (602.09) | Revenue Per Share | Quarterly Revenue Growth 0.367 | Return On Assets | Return On Equity |
The Oncology Institute's market price often diverges from its book value, the accounting figure shown on Oncology's balance sheet. Smart investors calculate Oncology Institute's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investment professionals apply varied valuation frameworks to compute inherent worth and acquire positions when market prices trade at discounts to calculated value. Since Oncology Institute's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Oncology Institute's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncology Institute is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncology Institute's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare The Oncology Institute and related stocks such as Mangoceuticals Common, Synlogic, and Lixte Biotechnology Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MGRX | (17.7 K) | (17.7 K) | (17.7 K) | (17.7 K) | (17.7 K) | (17.7 K) | (17.7 K) | (17.7 K) | (17.7 K) | (17.7 K) | (17.7 K) | (17.7 K) | (2 M) | (9.2 M) | (8.7 M) | (7.8 M) | (8.2 M) |
| SYBX | (2.9 M) | (2.9 M) | (3.7 M) | (6.4 M) | (15.8 M) | (25 M) | (26.3 M) | (40.4 M) | (48.4 M) | (48.7 M) | (56.5 M) | (58.1 M) | (66.1 M) | (57.3 M) | (23.4 M) | (21 M) | (22.1 M) |
| LIXT | (32.9 K) | (2.1 M) | (3.6 K) | (1.4 M) | (2.8 M) | (2.9 M) | (2.1 M) | (1.8 M) | (2.1 M) | (2.4 M) | (3.3 M) | (6.7 M) | (6.3 M) | (5.1 M) | (3.6 M) | (3.2 M) | (3.4 M) |
| ALLR | (81.2 K) | (81.2 K) | (81.2 K) | (81.2 K) | (68.7 K) | (1.1 M) | (3.7 M) | (4.9 M) | (2.3 M) | (14.3 M) | (6.6 M) | (26.6 M) | (16.1 M) | (11.9 M) | (24.5 M) | (22.1 M) | (21 M) |
| IRIX | 1000 K | 2.6 M | 1.4 M | 2.2 M | 10 M | 474 K | (11.7 M) | (12.9 M) | (12.8 M) | (8.8 M) | (6.3 M) | (5.2 M) | (7.5 M) | (9.6 M) | (8.9 M) | (8 M) | (7.6 M) |
| BCTX | (8.6 K) | (999 K) | (382 K) | (8.9 M) | (3.5 M) | (2.2 M) | (3.2 M) | (5.4 M) | (5.8 M) | (4.9 M) | (17.6 M) | (34.1 M) | (27.3 M) | (6.5 M) | (36.5 M) | (32.8 M) | (31.2 M) |
| LEXX | (508.3 K) | (343.6 K) | (343.6 K) | (1.9 M) | (1.8 M) | (1.2 M) | (1.9 M) | (6.6 M) | (4.1 M) | (3.9 M) | (4 M) | (7.3 M) | (6.7 M) | (5.8 M) | (11.9 M) | (10.7 M) | (10.2 M) |
| PCSA | (160 K) | (940 K) | (2.4 M) | (3.1 M) | (4.5 M) | (3.4 M) | (3.4 M) | (1.9 M) | (3.8 M) | (3.4 M) | (19 M) | (11.4 M) | (27.4 M) | (11.1 M) | (11.9 M) | (10.7 M) | (11.2 M) |
| CRIS | (12.1 M) | (9.9 M) | (16.4 M) | (12.3 M) | (18.7 M) | (59 M) | (60.4 M) | (53.3 M) | (32.6 M) | (32.1 M) | (29.9 M) | (45.4 M) | (60.3 M) | (47.4 M) | (43.4 M) | (49.9 M) | (52.4 M) |
The Oncology Institute and related stocks such as Mangoceuticals Common, Synlogic, and Lixte Biotechnology Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in The Oncology Institute financial statement analysis. It represents the amount of money remaining after all of The Oncology Institute operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| The Oncology Institute | TOIIW |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 18000 Studebaker Road, |
| Exchange | NASDAQ Exchange |
USD 0.1
Additional Tools for Oncology Stock Analysis
When running Oncology Institute's price analysis, check to measure Oncology Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Institute is operating at the current time. Most of Oncology Institute's value examination focuses on studying past and present price action to predict the probability of Oncology Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Institute's price. Additionally, you may evaluate how the addition of Oncology Institute to your portfolios can decrease your overall portfolio volatility.